Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response-Reference-Cited by-同舟云学术

Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Published:2014-03 Issue:3 Volume:38 Page:310-315
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

O’Dwyer Michael E.,Swords Ronan^ORCID,Nagler Arnon,McMullin Mary Frances,le Coutre Philipp D.,Langabeer Stephen E.,Alvarez-Iglesias Alberto,Fan Hongxin,Woodman Richard C.,Giles Francis J.,Conneally Eibhlin

Funder

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference15 articles.

1. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia;Foroni;Br J Haematol,2011

2. Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay;Dufresne;Arch Pathol Lab Med,2007

3. Evaluation of the Cepheid GeneXpert BCR-ABL assay;Jobbagy;J Mol Diagn,2007

4. Development of an integrated assay for detection of BCR-ABL RNA;Winn-Deen;Clin Chem,2007

5. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?;Cayuela;Haematologica,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease Response Assessment Modalities in Chronic Myeloid Leukemia: Past, Present, and Future;Indian Journal of Medical and Paediatric Oncology;2023-11-27

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances

;Cancer Management and Research;2020-05

3. Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia;Case Reports in Hematology;2020-03-23

4. Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia;International Journal of Hematology;2020-01-01

5. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB);Clinical Lymphoma Myeloma and Leukemia;2019-04